MediWound to Report Second Quarter 2025 Financial Results

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, will release its Q2 2025 financial results on Thursday, August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide corporate updates.

Investors can access the call via multiple channels including toll-free numbers for US and Israel, and an international dial-in. A webcast replay will be available in the Investors section of MediWound's website after the call.

MediWound to Report Second Quarter 2025 Financial Results

Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time

YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025.

Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.

Dial-in and call details are as follows:

Conference Call & Webcast Details
Toll-Free:                1-844-676-8833
Israel:                      1-80-9212373
International:         1-412-634-6869
Webcast:                Webcast Link

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx^®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

For more information visit www.mediwound.com and follow us on LinkedIn.

MediWound Contacts:                                                        

Hani Luxenburg                                                Daniel Ferry
Chief Financial Officer                                     Managing Director
MediWound Ltd.                                               LifeSci Advisors, LLC
ir@mediwound.com                                         daniel@lifesciadvisors.com        

Media Contact: 
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com

+1-929-588-2008

FAQ

When will MediWound (MDWD) report Q2 2025 earnings?

MediWound will release its Q2 2025 financial results on Thursday, August 14, 2025.

What time is MediWound's Q2 2025 earnings call?

The earnings conference call and webcast will take place at 8:30 a.m. Eastern Time on August 14, 2025.

How can I join MediWound's Q2 2025 earnings call?

Investors can join via phone (US Toll-Free: 1-844-676-8833, Israel: 1-80-9212373, International: 1-412-634-6869) or through the webcast link available on MediWound's website.

Where can I find the replay of MediWound's Q2 2025 earnings call?

An archived version of the webcast will be available for replay in the Investors section of the MediWound website after the call.